Amneal Pharmaceuticals, Inc. 8-K

What Happened

• Amneal Pharmaceuticals announced on April 21–22, 2026 that it entered into a Membership Interest Purchase Agreement to acquire 100% of Kashiv BioSciences, LLC. At closing Amneal will pay $375,000,000 in cash and issue 28,942,108 shares of Class A common stock. Sellers may also receive up to $350,000,000 in contingent regulatory milestone payments (for up to six Kashiv candidates) and are eligible for certain contingent royalty payments (25% of the amount by which annual aggregate gross profits for specified products exceed set hurdles) for 12 years after closing. The deal is not subject to a financing condition and is expected to close in the second half of 2026, subject to customary closing conditions including HSR clearance, other regulatory approvals and stockholder votes.

Key Details

• Cash + stock consideration at signing: $375,000,000 in cash and 28,942,108 Class A shares.
• Contingent payments: up to $350,000,000 for U.S. regulatory milestones (up to six product candidates) plus potential 12-year royalty payments (25% of excess gross profits above hurdles).
• Timing and approvals: expected in H2 2026; requires HSR clearance, other regulatory approvals and stockholder approvals; Outside Date Nov 17, 2026 (extendable to Jan 12, 2027 in limited circumstances).
• Governance & protections: Amneal’s independent Conflicts Committee unanimously found the agreement fair and will recommend shareholder approval; restrictive covenants (5‑year noncompete/non‑solicit) were signed with Chirag and Chintu Patel.

Why It Matters

• For investors, the transaction increases Amneal’s pipeline and future upside tied to Kashiv milestones and royalties, but also adds contingent obligations and will dilute current shareholders through the issuance of ~28.9M shares. The deal does not require financing to close (reducing financing risk), but it still depends on regulatory and shareholder approvals and customary closing conditions. Amneal also disclosed preliminary Q1 2026 results and hosted a conference call/webcast on April 22, 2026 to discuss the acquisition and those results; an investor presentation and press release were posted on the company website.